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A Task Force of the Osteoarthritis Research Society International (OARSI) has previously published a set of
guidelines for the conduct of clinical trials in osteoarthritis (OA) of the hip and knee. Limited material
available on clinical trials of rehabilitation in people with OA has prompted OARSI to establish a separate
Task Force to elaborate guidelines encompassing special issues relating to rehabilitation of OA. The Task
Force identiﬁed three main categories of rehabilitation clinical trials. The categories included non-
operative rehabilitation trials, post-operative rehabilitation trials, and trials examining the effective-
ness of devices (e.g., assistive devices, bracing, physical agents, electrical stimulation, etc.) that are used
in rehabilitation of people with OA. In addition, the Task Force identiﬁed two main categories of out-
comes in rehabilitation clinical trials, which include outcomes related to symptoms and function, and
outcomes related to disease modiﬁcation. The guidelines for rehabilitation clinical trials provided in this
report encompass these main categories. The report provides guidelines for conducting and reporting on
randomized clinical trials. The topics include considerations for entering patients into trials, issues
related to conducting trials, considerations for selecting outcome measures, and recommendations for
statistical analyses and reporting of results. The focus of the report is on rehabilitation trials for hip, knee
and hand OA, however, we believe the content is broad enough that it could be applied to rehabilitation
trials for other regions as well.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
A Task Force of the Osteoarthritis Research Society International
(OARSI) has previously published a set of guidelines for the conduct
of clinical trials in osteoarthritis (OA) of the hip and knee1. Limited
material available on clinical trials of rehabilitation in people with
OA has prompted OARSI to establish a separate Task Force to
elaborate guidelines encompassing special issues relating to reha-
bilitation of OA. The Task Force was composed of a multi-national
group of six academic physical therapists with expertise in OA, all.K. Fitzgerald, Department of Physi
6643; Fax: 1-412-648-5970.
.
ternational. Published by Elsevier Lof whom have extensive experience in designing and conducting
clinical trials in rehabilitation of people with OA.
The Task Force identiﬁed three main categories of rehabilitation
clinical trials. The categories included non-operative rehabilitation
trials, post-operative rehabilitation trials, and trials examining the
effectiveness of devices (e.g., assistive devices, bracing, physical
agents, electrical stimulation, etc.) that are used in rehabilitation of
people with OA. In addition, the Task Force identiﬁed two maincal Therapy, University of Pittsburgh, Bridgeside Point 1, 100 Technology Drive, Suite
td. All rights reserved.
Summary Box: Design and conduct of clinical trials for
rehabilitation in people with osteoarthritis
Categories of Clinical Trials
 Non-operative rehabilitation
 Post-operative rehabilitation
 Effectiveness of devices (e.g., assistive devices, bracing,
physical agents, electrical stimulation, etc.)
 Outcomes related to symptoms and function
 Outcomes related to disease modification
Entering Patients into the Trial
 Provide a thorough description of the participants (e.g.,
demographics, how the diagnosis of OA was determined,
comorbidities, baseline outcome measures)
 Describe methods of patient recruitment for the study
 Describe the inclusion and exclusion criteria
Conduct of the Study
 Overview of the study design
 Description and rationale for selection of control/
comparator groups (e.g., placebo vs comparator
intervention)
 Thorough description of interventions so that others can
replicate the interventions (algorithms for treatment se-
lection/progression, dosage (intensity, frequency, dura-
tion), adherence strategies, home programs, training of
treatment providers and treatment fidelity methods)
 Blinding procedures
 Managing and recording adverse events
Outcome Measures
 Should include reliable and valid measures of pain,
patient-reported function and disability, performance-
based measures of function, patient global assessment
 Explanatory trials should include measures to confirm
hypothesized mechanisms of treatment effect
 Results of outcome measures should be benchmarked
with known age and/or condition-matched normative
values or previously established outcome values if
available.
 The primary outcome should be expressed in terms of
mean, standard deviation, and 95% confidence intervals.
Authors should also consider reporting mean differences
between groups and the standard deviation and 95%
confidence intervals of the differences.
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include outcomes related to symptoms and function, and outcomes
related to disease modiﬁcation. The recommendations for reha-
bilitation clinical trials provided in this report encompass these
main categories.
The recommendations do not speciﬁcally address each possible
rehabilitation intervention that can be studied in clinical trials. In
developing the recommendations, the Task Force attempted to
make the descriptions of required elements broad enough to
encompass a variety of rehabilitation interventions or approaches.The Task Force considered rehabilitation to include interventions
that intended to reduce symptoms, improve functional capacity,
and/or promote healing with the goal of reducing or eliminating
disability. Rehabilitation interventions were assumed to include
therapeutic exercise, neuromuscular control and functional
retraining, physical modalities, electrical stimulation and
acupuncture, assistive devices, bracing and orthotics, self man-
agement education, strategies for improving self-efﬁcacy, pain
coping strategies, etc. It should be noted that while some elements
of studies using therapeutic exercise are covered in these guide-
lines, recommendations for studies addressing the use of exercise
andweight loss will also be covered in another article related to this
special issue.
Each member of the task force was assigned a section of the
guideline for development (e.g., entering subjects into the trial,
study design, interventions, adverse events and protocol violations,
outcome measures, and statistical considerations). Members of the
task force reviewed each section and made comments and sug-
gestions for revision. In instanceswhere therewas disagreement on
a speciﬁc item or issue, continued discussion and search of the
literature was used to resolve issues and a majority opinion was
used for ﬁnal decision.
Finally, the recommendations presented here were focused on
hip, knee and hand OA. These guidelines do not necessarily include
speciﬁc elements that might be needed in clinical trials addressing
rehabilitation approaches for OA of the spine, shoulder, and foot
and ankle. However, we believe that many of the recommendations
in the present guidelines would likely apply to trials examining the
effectiveness of rehabilitation interventions for these regions.
Entering patients into the trial
This section deals with aspects of the protocol related to
recruitment and enrollment of participants into the trial and
baseline data that will need to be obtained in order to clearly
describe the study participants.
Demographics
Demographic information provides a description of the general
characteristics of participants in the trial. Demographic information
can help to determine if randomization procedures were successful
in equating groups on basic characteristics that may have an impact
on the study outcome. This information can also be useful in
determining whether any of these characteristics might be useful
predictors of clinical outcome associated with the study
interventions.
Demographic characteristics should include participant age, sex,
race/ethnicity, height, weight, body mass index (BMI), educational
status, marital status, living arrangements, and employment status
(full-time, part-time, unemployed).
Diagnosis of OA
The study protocol should explain how the diagnosis of OA was
conﬁrmed for study participants. This should be done using vali-
dated criteria for diagnosis of OA such as the American College of
Rheumatology's (ACR) diagnostic criteria for hip, knee, or hand
OA2e4. For non-operative rehabilitation focusing on symptoms/
function, established clinical criteria (without use of radiographs or
laboratory data, such as the ACR clinical criteria) may be adequate
particularly if the interventions may be beneﬁcial regardless of
whether there is radiographic evidence of OA. It should also be
stated whether participants have unilateral vs bilateral involve-
ment. For studies concerning post-operative rehabilitation or a pre-
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results, the speciﬁc type of surgery or surgeries that will be tar-
geted in the study should be clearly identiﬁed.Radiographic/imaging severity
It may not be necessary for all rehabilitation studies to report
disease severity through radiographic or other forms of imaging,
particularly if the main outcomes of the study are only concerned
with symptom or function modiﬁcation. However, a description of
disease severity through imaging procedures will be necessary if:
(1) there is intention to include/exclude participants with radio-
graphic OA involvement of a speciﬁc joint or joint compartment
(e.g., medial tibiofemoral compartment, patellofemoral joint, etc.);
(2) the effects of the rehabilitation intervention on structural dis-
ease is to be assessed; and/or (3) the potential of structural disease
severity and/or extent of malalignment on mediation or modiﬁca-
tion of the intervention on the clinical outcome is to be evaluated.
For example, trials investigating the efﬁcacy of mechanical in-
terventions that are targeted towards a particular joint compart-
ment (e.g., unloading knee brace that aims to unload either the
medial or lateral tibiofemoral joint) will usually require imaging for
these reasons. In post-operative rehabilitation trials, imaging pro-
cedures may be required if participant inclusion/exclusion criteria
are based on proper placement of surgical components, quantiﬁ-
cation of disease severity in the non-operative limb, or if an aim of
the study is to examine the effects of rehabilitation on surgical
components. If a description of imaging-based disease severity is to
be included, then it should be reported using a validated severity
quantiﬁcation scale, following the recommendations reported in
the article(s) in this special issue on imaging.Co-morbidities/other medical history
Co-morbid conditions and concurrent interventions may inﬂu-
ence the outcome of rehabilitation interventions and should be
accounted for in the study protocol. Where concurrent in-
terventions are concerned, providing as much detail about the
application of the intervention would be important in determining
its role as a potential confounder. In particular, for trials of devices
(e.g., braces, orthoses, footwear, gait aids), current use of these in-
terventions may be considered an exclusion criterion for trial
enrollment due to difﬁculties administering the intervention of
choice when the participant is already receiving a similar inter-
vention. See Table I for a list of information that should be obtained
on study participants.Table I
Documentation of comorbidities and potential confounders of treatment outcome
 Chronic Diseases or conditions (e.g., diabetes, osteoporosis, heart disease, hypertens
 History of previous injury or surgery related to the study target joint with OA
 Other current pain sites
 Past and current tobacco and alcohol use
 Past and current medications for treatment of joint pain/OA
 Past and current non-pharmacological treatments (e.g., exercise, orthotics, etc.) of joi
these interventions such as dosage and duration, setting in which the treatmen
helpful in determining their role as a potential confounder)
 History of most recent cortico-steroid and/or hyaluronan injection for target joint p
 Previous use of study interventions
 Subject expectations of treatment effectiveness
 Occupational activity (sedentary, moderately physical labor, hard physical labor)
 Recreational activity (sedentary, moderately physically active, highly physically acti
 For post-operative rehabilitation trials:
 Surgical complications or other intra-operative ﬁndings that may inﬂuence outco
 Was pre-operative rehabilitation provided
 If study focus is on outpatient rehabilitation, report any inpatient or home-basedFor post-operative rehabilitation trials, information concerning
surgical complications or other intra-operative ﬁndings that may
have an inﬂuence on the outcome of rehabilitation should be re-
ported. If participants in a post-operative rehabilitation trial receive
pre-operative rehabilitation, this should also be reported. When the
focus of the post-operative rehabilitation trial is on outpatient reha-
bilitation, inpatient or home-based therapy the participant may have
received before entering the outpatient trial should be reported.
Baseline symptoms, function, physical activity levels, health-related
quality of life
Participants in rehabilitation studies should be described with
respect to their baseline pain, function, physical activity, and
health-related quality of life. Reliable and validated measures
should be used for these purposes. Examples of reliable and valid
measures for these constructs are provided in the outcome mea-
sures section below. If study interventions are designed to address
speciﬁc impairments (e.g., joint range of motion, muscle strength,
balance, aerobic capacity, joint proprioception, etc.) or if it is
believed that the impairments may be treatment outcome modi-
ﬁers or mediators, then those impairments should be measured at
baseline using reliable and valid methods. If study interventions are
designed to address speciﬁc impairments (e.g., joint range of mo-
tion, muscle strength, balance, aerobic capacity, joint propriocep-
tion, etc.) or psychosocial variables (e.g., depression, anxiety, fear of
physical activity, pain catastrophizing, self-efﬁcacy, etc.) or if it is
believed that these may be treatment outcome modiﬁers or me-
diators, then these should be measured at baseline using reliable
and valid methods. Other variables that might be potential con-
founders, or treatment moderators or mediators such as subject
expectations of treatment effectiveness, occupational activity
(sedentary, moderately physical labor, hard physical labor), and
recreational activity (sedentary, moderately physically active,
highly physically active) may also be useful to record at baseline.
Methods of recruitment
The methods used to recruit participants and the sources of
recruitment should be clearly explained (e.g., use of registry lists,
public advertisements/announcements, direct referral from
healthcare providers, etc.)
Inclusion/exclusion criteria
Inclusion and exclusion criteria should be clearly deﬁned. Par-
ticipants may be included based on age limits, sex, diagnosticion, neurological disorders)
nt pain/OA (Providing as much detail as possible concerning the application of
ts were applied, whether they were active or passive interventions, could be
ain/OA and other joints
ve)
me measures
therapy that may have been received
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examining post-operative rehabilitation need to be clear on the
target surgical procedure(s) that will serve as the basis for inclusion
into the study. Inclusion criteria for levels of baseline symptoms,
function, and/or disability should be established to ensure that
minimum clinically important differences can be detected at
follow-up testing.
Exclusion criteria should also be clearly deﬁned. Participants
may be excluded based on age limits, sex, and presence of in-
ﬂammatory arthritides (gout, RA, psoriatic arthritis, etc.). Co-
morbidities that serve as a basis for exclusion should also be
described. It is important to note that, in some trials, just the
presence of pain or pathology at other sites may be considered an
exclusion criterion. For example, in a trial evaluating shoe orthoses
for people with knee OA, concurrent pain and/or pathology in the
foot or ankle may be a contra-indication to treatment with shoe
orthoses and thus may be exclusion criteria. Previous or current
treatments may also serve as a basis for exclusion and should be
described. This may include surgical/medical procedures, phar-
macological interventions, or speciﬁc previous or concurrent
treatments (e.g., if testing a brace, exclude peoplewho are currently
using a brace or if testing the effect of strength training, exclude
people who have been currently participating in a regularly
scheduled strength training program). Participants may also be
excluded on the basis of contraindications to the speciﬁc study
interventions (e.g., if poor skin condition, then might exclude from
a taping or bracing trial).
Conduct of the study
Study design
Studies should be randomised, controlled, and parallel in design.
At a minimum, studies should be assessor-blinded, and ideally,
participant-blinded as well, although it is acknowledged that this is
often not possible in rehabilitation studies. Most clinical trials aim
to test the superiority of one treatment over another, and thus are
often termed superiority trials. However, although the randomized,
controlled parallel design would be the gold standard in most in-
terventions studies, different trials and designs could be considered
depending on the aims of the study. For detailed descriptions of
other trial design options, the reader is referred to the article in this
special issue on research designs and statistical considerations.
Clinical trial designs may be categorized as “explanatory” or
“pragmatic” trials5. Explanatory trial (or efﬁcacy trial) designs
should be used when investigators wish to determine whether an
intervention produces the hypothesised beneﬁt that it was inten-
ded to produce and therefore tests causal or mechanistic hypoth-
eses5. Explanatory trials examine interventions under ideal
(research) circumstances, with a higher emphasis on the internal
validity of the research design. In contrast, pragmatic trial (or
effectiveness trial) designs should be employed if investigators
wish to measure whether a treatment is beneﬁcial when tested and
delivered in “real world” clinical settings5. Pragmatic trials are
more lenient on control of design elements, such as clinician
experience, deviations from intervention protocol, participant
characteristics/comorbidities, etc. This is because these elements
are not always well controlled in real clinical situations and the
intent of the pragmatic trial is to determine how well the in-
terventions may work under these less than ideal, yet realistic
conditions. Pragmatic trial designs tend to emphasize external
validity at the expense of some internal validity. It is important to
recognise that explanatory and pragmatic trials exist on a contin-
uum and in many cases a trial design may incorporate elements of
both. Thus investigators need to consider what their intended aimsare for their study in order to determine where on this continuum
they would like to have the trial design fall. For the remainder of
this manuscript we will try to indicate where applicable how in-
vestigators may alter some design characteristics based onwhether
more explanatory or pragmatic designs are pursued.
Frequently for rehabilitation interventions, comparative effec-
tiveness study designs (where two or more groups are randomly
assigned to receive different interventions without knowing the
research hypothesis) may be appropriate. Comparative effective-
ness trials may be particularly useful for testing the effectiveness of
novel treatments relative to established interventions, or when
participant blinding is not possible. Occasionally, crossover trials
may be appropriate. Crossover trials may be suitable for in-
terventions where treatment effects are likely to occur relatively
quickly and subside rapidly once the intervention is ceased and
with little likelihood of long-term carry-over on the study out-
comes (e.g., knee bracing, shoe orthotics, patellar taping, gait aids).
Crossover trials should randomly assign the treatment sequence to
participants and carry-over effects should be minimized by a suf-
ﬁciently long “wash-out” period between treatments. Investigators
may wish to determine whether an intervention is therapeutically
similar or equivalent to another existing or accepted treatment
with established efﬁcacy. In these instances, equivalence or non-
inferiority trials (as opposed to superiority trials) are the most
appropriate trial design and it is critical that an a priori margin of
equivalence or non-inferiority is determined. These types of study
designs are only appropriate if the “new” treatment offers clear
advantages or beneﬁts (often in terms of cost or practical applica-
tion) over the existing or reference treatment.
The study must be approved by the local human research ethics
committee prior to recruitment commencing, and all study par-
ticipants must provide informed consent to participate. The trial
must be registered prospectively (prior to participant recruitment
commencing) with an appropriate clinical trials registry (e.g.,
http://clinicaltrials.gov/, http://www.anzctr.org.au/, or http://www.
isrctn.com/). In addition, investigators may wish to publish the trial
protocol (e.g., BMC Musculoskeletal Disorders, Journal of Physio-
therapy, Trials, BMJ Open, etc) to alert the scientiﬁc community that
the trial is underway and to publish the protocol in sufﬁcient detail
that is often not possible when writing up the ﬁnal results of the
trial.
The study design should include a screening phase to ensure
participants fulﬁll selection criteria and are eligible to enter the
study. The screening phase may encompass one or more of tele-
phone interview, self-reported questionnaires, radiographic review
and/or a clinical examination. Employing multiple screening pro-
cesses increases the likelihood that participants fulﬁll selection
criteria and provides some reassurance that participants are likely
to adhere to the trial protocol and its requirements, which may be
particularly important in studies of rehabilitation. For trials of de-
vices, such as braces or orthoses, where participant application of
and tolerance of the devicemay inﬂuence adherence and trial drop-
out rates, a “run-in” approach may be employed in the screening
phase, where participants are provided with a similar device to the
one being studied (i.e., an alternate type of orthotic so as not to
unblind participants) and only those who are sufﬁciently adherent
to use of the device over an initial short time-frame are enrolled.
While such an approach increases the likelihood of maximizing
intervention adherence and minimizing drop-outs in the trial, it
does result in a participant sample that is less generalizable to the
wider population and researchers should consider these draw-
backs when designing their study. When pain is to be measured
as a primary study outcome, and/or a minimum pain score is used
as a study inclusion criteria, it may be helpful to screen baseline
pain at several occasions. There can be clinically signiﬁcant weekly
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baseline in this manner may maximize the accuracy and reliability
of baseline pain data.
Depending upon the number of outcomes being assessed, and
the burden imposed by the assessment tasks on the participant
(with respect to time constraints and physical demands), one or
more assessment sessions may be required to collect all of the
required baseline data. When participant-reported outcome mea-
sures (e.g., questionnaires) are being used, it may be appropriate for
participants to complete the questionnaires at home and post them
back, or online and submit them to investigators electronically. In
these cases, investigators should check each questionnaire carefully
for any incomplete items and ensure participants answer any
incomplete questions. Wherever possible, it is desirable that the
same assessor examines the same participant at each visit, including
at follow-up assessments, to minimize unwanted variability in data.
Ideally, and particularly when pain is assessed as a study outcome,
participants should be re-assessed on the same day of the week and
preferably at the same time of day over the course of the trial.
Control conditions (comparator groups)
Studies should always include a comparison group. The com-
parison group may be a no treatment control (i.e., participants
continue with their usual care of their symptomatic OA which may
involve drugs or other interventions but are not allocated to receive
the active intervention being evaluated), an active comparator
where the comparator has been previously shown to be effective, or
a placebo (sham) treatment. It is also possible in rehabilitation trials
to have the comparison groups include surgical intervention (and
often times the post-surgical rehabilitation that accompanies sur-
gical treatment) where the non-operative group might be the
experimental group and the surgical intervention group serves as
the active comparator.
Although a placebo-control is generally considered the ideal
comparator group in drug trials for participant blinding in order to
provide a less biased estimate of treatment effect, placebo in-
terventions in rehabilitation trials are difﬁcult to devise and
implement. In fact, for complex interventions involving a package
of care (e.g., physiotherapy, progressive individualised exercise
programs that may also be combined with use of splinting, braces
or orthoses) where characteristic (speciﬁc treatment effects) and
incidental (placebo, non-speciﬁc, context factors) treatment effects
are intertwined and often indistinguishable, the use of a placebo
(sham) control may fail to detect the whole characteristic treat-
ment effect and may lead to false negative results8. In these in-
stances, pragmatic designs that utilise usual care or another active
comparator may be more appropriate. When studies examine in-
terventions that involve only the provision of a device (e.g., shoe
orthotics, braces, splints, and/or footwear with minimal ongoing
input from a health professional), the characteristic treatment ef-
fects are usually distinct from incidental effects and a placebo-
control is often possible. An ideal placebo (sham) comparator
should be indistinguishable from the active treatment, credible to
the participants and inert with no speciﬁc therapeutic effects. For
more information on the strengths and weaknesses of various
comparator groups in clinical trials, the reader is referred to the
article in this special issue concerning statistical and experimental
design considerations.
Blinding
Wherever possible, the assessor, participant and therapist
should be blinded to which group is receiving the experimental
treatment in order to minimize the potential risk of bias (e.g.,performance and response bias). However, it is often difﬁcult to
achieve participant blinding in rehabilitation trials, especially when
participants of both treatment arms are being treated in the same
setting and/or by the same health care providers. Furthermore,
under most circumstances it is not possible to blind the therapist
who is applying the treatment. Given that meta-analyses show that
inadequate allocation concealment and lack of blinding are asso-
ciated with over-optimistic estimates of treatment effects for
patient-reported outcomes9, efforts to minimize bias in trials with
participant-reported outcomes are particularly crucial.
The assessor should always be blinded in a clinical trial and this
is almost always possible in rehabilitation trials. In rare cases where
assessors cannot be blinded, it is important that objective and
reliable outcome measures are utilized to minimize risk of bias.
Duplicate assessment of outcomes by two independent assessors
and reporting of the level of agreement achieved by the assessors
should also be considered in these instances. In trials where
patient-reported outcome measures are used, and the patient is
blinded to treatment allocation, the assessor is considered to also
be blinded. Irrespective of participant and assessor blinding, sta-
tistical analyses should ideally be performed by a blinded statisti-
cian/investigator.
Although ideal, blinding of the treating therapist is almost al-
ways impossible in rehabilitation studies, except for in studies of
electrotherapy where the device delivering the intervention may
be custom-developed to deliver the intervention (or not) based on
the input of a randomization code by the blinded therapist. Table II
provides suggested strategies that may be employed to minimize
bias in trials where therapist and/or participant blinding is not
possible.
When reporting the results of the trial, it is important to clearly
state who was blinded (e.g., participants, assessors, therapists). In
addition, the methods used for masking must be clearly stated. It is
possible that, in addition to a blinded assessor (to assess the
participant on primary outcomes regarding efﬁcacy and adverse
events), an unblinded assessor may be needed (e.g., to measure
biomechanical mediators of effect whilst participant wears their
allocatedmechanical intervention that is visually identiﬁable as the
active intervention (e.g., orthotics, knee brace, footwear)) in some
studies.
Interventions
Considerations around the interventions and their delivery will
be inﬂuenced by the position of the trial design along the contin-
uum from explanatory to pragmatic. In rehabilitation trials, the
experimental intervention can range from a single modality
through to a complex package of care. While it may be ideal to
provide standardized treatment in a clinical trial, this is not
necessarily reﬂective of clinical practice in which rehabilitation is
individualized taking into account patient presentation on clinical
examination, patient preferences and past history of treatment.
Furthermore, it does not alignwith clinical treatment guidelines for
OA where individualized treatment is recommended due to
different subgroups of OA patients as well as varying clinical pre-
sentations10. A trial that allows greater ﬂexibility in applying the
treatment will lie closer to the pragmatic end of the trial design
spectrum whereas a standardized treatment with strict in-
structions for every element will be closer to the explanatory end.
The comparator intervention will also be determined by the trial
design. For a more pragmatic trial, the comparator will often be
‘usual care’ while for an explanatory trial, it may be a placebo
intervention. If the comparator will be “usual care,” it is important
to recognize that usual care can have multiple meanings. For
example, in some cases, it may be interpreted as being in
Table II
Strategies to minimize bias when therapist or participant blinding is not possible
 Blind the participants to the research hypothesis if possible and ethical, such as in a study comparing two different rehabilitation interventions that could each feasibly
be of beneﬁt to the participant.
 Ensure that treatment groups are treated equally as far as possible with respect to number of treatment sessions with the treating therapists, duration of treatment,
quantity and quality of participant materials (e.g., written materials, equipment etc). Detailed treatment protocols for each group will be required and information
about how standardisation of therapy across groups was achieved and monitored must be recorded.
 Treating therapists must be educated and trained in the importance of treating participants from each treatment group equally and not to “favour” one group over
another. Random auditing of therapist treatment sessions can provide assurance that groups are being treated as equally as possible by therapists.
 In cases where the same therapists are delivering the treatment interventions to both treatment groups, strategies should be put in place to prevent participants from
one treatment group meeting participants from the other group and potentially discussing their treatment allocation (e.g., arranging appointments so that participants
from each group are never treated at the same time or could meet each other in the waiting room)
 Researchers may choose to use separate pools of therapists to deliver each intervention arm (cluster designs).
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mean management by a primary care physician. We recommend
that when “usual care” is to be used as the comparator that authors
provide detailed descriptions of what constitutes “usual care”
treatment in their studies.
It is also important to consider the extent to which strategies to
improve adherence to the interventions will be used and the nature
of such strategies (e.g., the use of ‘booster’ sessions with a therapist
to improve home exercise adherence or phone calls to remind
participants to wear orthotics). In trials that are more explanatory,
consideration of relevant strategies to maximize participant
adherence to the intervention is paramount.
In all trials, a precise description of the intervention and the
comparator, as well as any adherence strategies, needs to be pro-
vided so as to be reproducible by another team. Where individu-
alized treatment is provided, a description of the procedures for
tailoring the intervention to individual participants should be fully
described11. Descriptions may include: treatment setting and pro-
vider, number of health provider visits, group or individual ses-
sions, duration of visits, frequency of visits; type of exercise,
position of exercise, number of exercises, sets and repetitions, in-
tensity of the program, degree of supervision, progression; model,
manufacturer details andmaterial for braces, orthotics or other aids
and/or appliances; descriptions of ﬁtting instructions and any in-
structions provided to participants regarding frequency of use/
wear of devices (e.g., shoe orthoses may be initially worn for 1 h per
day and increased gradually over time until wearing them full-
time); type of technique, patient position, grade and number of
sets and repetitions for manual techniques. Some authors have
used a goal-based rehabilitation program to tailor interventions to
the individual patient12. For example, the program may include
pre-deﬁned goals for joint motion, muscle function, and functional
performance for patients to progress the rehabilitation activities
from lower levels to higher levels of intensity12. When using this
approach, the operational deﬁnitions for achieving the goals must
be described so that others can reproduce the approach.
It is also important to record the adherence to the intervention
through the trial to assess the accuracy and generalizability of the
results. The intensity to which this is done will be greater in
explanatory compared to pragmatic trials. However, measuring
participant adherence is not necessarily straightforward and the
decision about the best method to use will need to take into account
reliability and validity of the tool, participant-burden and resources.
For example, self-reported measures of exercise adherence or splint,
orthotic or brace usage may be recorded in a log book. Accelerom-
eters or online registration of participation's physical activity may be
used to assess the amount of physical activity. It may also be possible
for researchers to visually inspect devices (e.g., footwear or orthoses)
at completion of the trial for degree of wear as another indicator of
adherence. Developing proxy measures for adherence to exercise
programs (similar to how blood sugar may be used as a proxymeasure for adherence to a dietary intervention in patients with
diabetes as opposed to self-reported food intake) may be an inter-
esting idea to explore. At this time there is little evidence to guide
this approach but this is an area that would be worth further
investigation. It is important to consider the extent to which moni-
toring of patient adherence actually inﬂuences adherence behavior
itself. Publishing the treatment protocol separately prior to the main
trial ﬁndings or as an appendix to themain trial paper is an excellent
way to provide more detailed description of the treatment than is
generally allowed in the main paper.
Unlike pharmacological therapies, the treatment effects are also
likely to be inﬂuenced by the healthcare practitioner who performs
or delivers the intervention. Given then that the healthcare prac-
titioner is an integral part of the intervention, eligibility criteria and
training of the practitioner should be considered and reported. In
line with the CONSORT extension for non-pharmacological treat-
ments11, practitioner characteristics including gender, years of
experience, previous research experience and qualiﬁcations need
to be reported. In explanatory trials, a high level of practitioner skill
and expertise in applying and monitoring the intervention is
desirable to maximize treatment ﬁdelity. Pragmatic trials will be
more ﬂexible in selecting practitioners and will generally include a
range of skill levels. Training should be provided to practitioners
and may take the form of study manuals, DVDs and/or face-to-face
or on-line training programs. In some trials it may be necessary to
formally ascertain that the practitioner has attained a certain level
of skill following training before treating participants as part of the
trial. Adherence of practitioners to the intervention throughout the
trial should also be maximized, particularly in explanatory trials.
This can be achieved through strategies such as holding regular
meetings, booster training sessions, and providing treatment notes.
Assessment of practitioner adherence to the protocol is important
and can be achieved through methods such as audio/videotaping
treatment sessions and auditing treatment notes. The number of
practitioners chosen to deliver the intervention will vary depend-
ing on the trial requirements. Having a greater number of practi-
tioners will increase the variability in treatment delivery but will
enhance the external validity of the study.
Participation retention
Strategies for participation retention need to be described for all
rehabilitation trials. In explanatory studies, participation retention
strategies need to be maximized. For example, as mentioned
earlier, in device trials, “run-in” methods (where participants are
provided with a similar device to the one being studied (i.e., an
alternate type of orthotic so as not to unblind participants) and only
those who are sufﬁciently adherent to use of the device over an
initial short time-frame are enrolled) might be incorporated to
maximize intervention adherence and participant retention. In
more pragmatic trials, participation retention strategies should be
G.K. Fitzgerald et al. / Osteoarthritis and Cartilage 23 (2015) 803e814 809enhanced but not to level that it might be an intervention it itself.
Method of communication and patient contact, visit reminders,
transportation issues and other corresponding issues should be
addressed and the reason for eventual discontinuation of partici-
pation given. In case of patient discontinuation in a trial, clinical
assessment should be made or a preplanned and standardized
telephone interview should be attempted. These strategies need to
be included in the planned protocol as well as in the consent form.
Concomitant therapy
Symptomatic drug therapies are common for patients with
symptomatic OA and may be used by participants in both non-
operative and post-operative rehabilitation trials. The use of phar-
macological treatment may interfere with study interventions and
therefore affect outcome measures, but discontinuation might
neither be ethical nor practical. In explanatory trials these
concomitant therapies should be limited, but in more pragmatic
trials continuing concomitant therapies could be desirable to
enhance external validity. It is important to monitor the use of any
other treatments that the patients would need or take during the
trial and adjust for in the analysis to ensure that the effects of the
rehabilitation interventions on symptoms or disease progression
do not bias the outcome. The use of weekly or monthly web based
communication systems or written log-books may be advisable to
obtain the most reliable data.
Adverse events
Adverse events should be deﬁned a priori and carefully recorded
by the therapist and/or the participant and if appropriate reported
to regulatory authorities in accordance with requirements in good
clinical practice and according to the speciﬁc regulations and re-
quirements in the different countries. Adverse events in rehabili-
tation trials are usually relatively minor, for example exacerbation
of pain or swelling, and would not require report to regulatory
authorities. A pain monitor scale where zero is “no pain” and ten is
“worst considerable pain” should be used. Pain up to two is
considered “safe” and up to ﬁve is considered “acceptable” as long
as it is temporary13. Swelling should be monitored and the Stroke
test could be used as an effusion grading scale.14
In instances where adverse events will need to be reported to
regulatory/oversight boards, a determination of whether or not the
event was related to study interventions or procedures will have to
be determined. Data Safety and Monitoring Boards frequently
require investigators to record all adverse events whether they
believe the event is related to study interventions or not. This
determination of whether the adverse event is study related should
be made by an individual who is blinded to study group assign-
ments to avoid any potential for bias in making this determination.
Although the treating therapist may be the one to ﬁle an initial
report, the therapist is not blinded to group assignment and should
not make a ﬁnal decision as to whether the event was study-
related. The therapist can report the nature of the adverse event
and the conditions under which it occurred without disclosing the
treatment group assignment. The principal investigator or other
designated blinded investigator could then determine if the
adverse event was treatment-related without knowing which
treatment group the participant belongs to and hence avoid (or
minimize) the potential bias.
Protocol violations
Protocol violations in rehabilitation studies can include viola-
tions in randomization, intervention, and outcome procedures. It isimportant to record protocol violations as they occur for all par-
ticipants in a study as the nature and frequency of these violations
could have implications for decisions regarding participant termi-
nation, or in studies where intention-to-treat approaches are
employed, determining if protocol deviations need to be controlled
for in the ﬁnal data analysis. Likewise, it would also be important to
record the number of participant dropouts between groups and
determine if there were group differences on this factor that may
bias any group effects.
Violations in randomization may include randomization of
participants who do not meet the study inclusion criteria or when
participants are mistakenly given the treatment approach contrary
to the one in which they were randomly assigned. Violations in
intervention procedures may include the administration of
improper treatment dosage (intensity, frequency, duration) or
administration of co-interventions not speciﬁed as approved co-
interventions in the study protocol. In some cases, participants
may cross-over to the other intervention group during the course of
the study. This might occur in study designs where one group re-
ceives an experimental intervention combined with standard
treatment and is compared to a group receiving only the standard
treatment. A participant assigned to the experimental treatment
group may refuse to continue to receive the experimental inter-
vention and thus only receives the standard treatment for the
remainder of the study. Outcome procedure protocol violations
could include failure to administer a speciﬁc outcome measure at a
given follow-up time point. Outcome procedure protocol violations
might also include obtaining measurements out of the appropriate
time window for the follow-up period or failing to obtain any
outcome measures for a given follow-up period.
A report should be completed for each protocol violation that
occurs for each participant in the study. The report should be kept
in the participant's study record. When completing a report the
investigators should include the date the protocol violation
occurred, the name of the individual completing the report, and a
description of the nature of the protocol violation. Protocol viola-
tions related to outcome measures should include the speciﬁc
measure or measures that are missing and the follow-up period
associated with the violation. Any explanations for why the pro-
tocol violation occurred should also be included in the report.
In the ﬁnal publication, it would not be necessary to report each
and every protocol violation that occurred over the course of the
study. However, any protocol violations that resulted in the
termination of participant involvement in the study should be re-
ported. Likewise, if any category of protocol violationwas identiﬁed
as a potential co-variate that needed to be controlled for in the ﬁnal
analysis, this should also be reported. In studies where intention-
to-treat approaches to data analysis are employed, the data from
participants who incurred protocol violations over the course of the
study would continue to be included in the ﬁnal analysis.Outcome measures
Primary outcomes
Explanatory or efﬁcacy clinical trials should have a clearly
deﬁned primary outcome variable. This outcome variable will
depend on the nature of the study, but should be a direct and im-
mediate consequence of the intervention5. For pragmatic trials, the
primary outcome should be clinically meaningful, but may not be
the direct result of the intervention. For example, in an explanatory
trial evaluating a stretching intervention, the primary outcome
should be range of motion. For a pragmatic trial of a similar nature,
the primary outcome may be a measure of functional performance
or a patient-reported outcome measure.
Table III
Categories of outcome measures in OA rehabilitation trials
Recommended Core Set of Measures
 Pain
 Patient-reported outcome measures
 Performance-based measures
 Patient global assessment
Additional Measures Strongly Recommended
 Health-related quality of life
 Ratio/number of responders
Optional Measures
 Signs of inﬂammation (redness, swelling/joint
effusion, increased skin temperature)
 Self reported stiffness
 Range of motion
 Biomechanical parameters derived from gait analysis
 Laxity
 Muscle strength
 Proprioception
 Self-reported instability (buckling or giving way, etc.)
 Body weight/BMI
 Time to surgery
 Medication consumption
 Physical activity
 Psychological measures
 Biomarkers
 Imaging of structural change
 Cost-effectiveness
 Adherence
 Acceptability/comfort (e.g., for a study of orthotics or devices)
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outcome measures. This approach may require adjustments to the
statistical signiﬁcance to account formultiple analyses. For all trials,
the outcome measure must be operationally deﬁned if there is no
universal standard for quantiﬁcation.
Secondary outcomes
Inclusion of one or more secondary outcomes is recommended
in rehabilitation studies. Acquisition of secondary outcomes should
not interfere with the primary outcome measure and the study
should be appropriately powered if the intention is to evaluate the
effect of the intervention on these outcomes.
Outcome measures of OA
Outcome measures should consist of variables that have been
reported to be reliable, valid and responsive within the clinical
population included in the study. Table III provides of list of
outcome measures that may be used in OA rehabilitation trials.
Pain. The magnitude of pain in the joint of interest should be
quantiﬁed. Pain can be quantiﬁed using a Likert scale of severity in
which the options include “None”, “Mild”, “Moderate”, “Severe”, or
“Very Severe.” Other options include a 100 mm Visual Analog Score
(VAS) in which the end-points are anchored with “No Pain” and
“Worst Pain Imaginable.” Alternatively, an 11-point Likert scale can
be used with anchors of “0 e No Pain” and “10 e Worst Pain
Imaginable.” The speciﬁc type of pain (e.g., pain at rest, pain with
motion, etc.) and time-frame of pain recall (e.g., maximal pain over
the last week, current pain, etc.) should be documented. The time
allowed between the episode of pain and the recall of pain should
be minimized, as longer recall times reduce the ability to accurately
recall pain severity. Optimal time for pain recall is less than 48 h15.
Activity-speciﬁc questions of pain may be appropriate and can be
measured using a Likert score or VAS (e.g., pain during weight-
bearing or pain during stair-climbing). Validated instruments
with pain subscales can also be used (e.g., Western Ontario and
McMaster Universities Osteoarthritis Index (WOMAC) pain sub-
scale16, Knee Injury and Osteoarthritis Outcome Scale (KOOS) pain
subscale17, Hip Disability and Osteoarthritis Outcome Score (HOOS)
pain subscale18, or the Boston University Osteoarthritis Computer
Adapted Test (BU OA-CAT) Functional Pain Scale19. Valid and
responsive pain scales that capture both constant and intermittent
pain, such as the Intermittent and Constant Pain Score (ICOAP) may
also be of value in trials evaluating symptom modifying in-
terventions20. The reader is referred to the articles on knee, hip, and
hand OA trials in this special edition for detailed descriptions of
potential symptom measures.
Patient-reported physical function. Valid, reliable and responsive
self-report of physical function questionnaires or subscales are
recommended for studies of OA. These questionnaires may be
disease-speciﬁc (e.g., WOMAC or Arthritis Impact Measurement
Scale (AIMS)21) or joint- and disease-speciﬁc (Knee Injury and
Osteoarthritis Outcome Score (KOOS)22 and HOOS23 Activities of
Daily Living and Sport and Recreation and Physical Function sub-
scales, Knee or Hip Outcome Scale Activities of Daily Living Scale (K/
HOS-ADLS)24,25, Australian/Canadian Hand Osteoarthritis Index
(AUSCAN)26, or Functional Index of HOA (FIHOA)27,28.) General or
joint-speciﬁc functional scales are appropriate if they have been
validated in similar OA populations (e.g., Lower Extremity Func-
tional Scale (LEFS)).29
Patient global assessment. The patient's perception of his or her
overall functional ability should be assessed using a single Likert or
VAS metric. A single optimal method has not been established,although a standard question should be asked at all evaluation
points in the trial. For example, “How would you rate your current
level of function during your usual activities of daily living?” can be
quantiﬁed on a 100mmVASwith end-points anchored as “Inability
to perform any daily activities” and “No problem with any daily
activity” to capture a participant's overall global rating. Single
questions related to global rating of change may also be used to
capture the patient's perception of change overall or pain from
baseline to follow-up examination. If using the global rating of
change, it should be clear to the patient the time frame over which
you are asking about the change in condition. For example the
query might include something like “based on how you were doing
at the start of your treatment, how much improvement do you feel
you have made up to now,” in order to let the patient know you
want them to refer to change from baseline to the present. It has
also been suggested to provide a memory marker (e.g., asking the
patient some question about their condition at baseline, then
reminding them of this statement at the follow-up) to the patient to
assist in improving the patient's recall of their baseline condition.30Performance-based measures. Performance-based and self-
reported functional assessments evaluate different domains of
disability and are associatedwith different underlying impairments
in patients with OA31. Therefore, performance-based tests are rec-
ommended as outcomes in rehabilitation clinical trials.
Performance-based outcomes may include time to complete a task,
the distance walked in a speciﬁed time, or the number of successful
attempts in a given time to complete a functional movement. The
OARSI initiative to develop a recommended set of physical perfor-
mance measures for hip and knee OA identiﬁed a minimal core set
of measures to evaluate functional performance of sit-to-stand,
short walking distances and stair negotiation tasks. These recom-
mended variables include the 30 s chair stand test, the 4  10 m
fast-paced walk test and a timed stair task, respectively32. There
currently is not an established minimal core set of performance-
based measures for hand OA, however some options may include
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Moberg's Pick-up Test.33e35
Generic health status measures. Measurements of generic health
status are strongly recommended for inclusion in rehabilitation
trials for persons with OAwhen the duration of the trial is at least 6
months36. The Short-Form 36 Health Survey (SF-36)37, and the
EuroQOL38 are examples of health status measures that have been
used and validated in patients with OA. Health status measures
should be included if cost-effectiveness is used as a primary or
secondary outcome.
Clinical joint examination. Joint-speciﬁc impairments such as joint
circumference, effusion, range of motion, strength, laxity and pro-
prioception may be important outcomes in explanatory trials. The
utility of thesemeasures in pragmatic clinical trials is dependent on
the nature of the intervention and relation of these impairments to
down-stream functional performance. Joint stiffness has been
recommended to be assessed using patient-reported measures
(e.g., items onWOMAC, KOOS or HOOS36, but self-reported stiffness
measures may not be as reliable or valid as self-reported pain
measures. Joint alignment is associated with OA disease progres-
sion and there is some evidence that joint mal-alignment can affect
the outcome of exercise on pain responses39. Therefore, measure-
ment of alignment may be important in rehabilitation trials. There
are several methods for measuring joint alignment and the reader
is referred to the other articles on imaging knee and hand for dis-
cussion on these methods.
Body weight and BMI. Body weight and BMI should be assessed at
baseline and at follow-up evaluations for clinical trials that target
symptom-modifying interventions. Change in body weight or BMI
may be used as an outcome measure or as a covariate, when
appropriate, in statistical analyses.
Time to surgery. Symptom-modifying treatments that attempt to
eliminate or delay the need for surgical procedures (e.g., high-tibial
osteotomy or joint arthroplasty) can be assessed using time-to-
event analysis. However, the decision to undergo surgery is inﬂu-
enced by many environmental, health-related and psycho-social
factors (e.g., ability to pay for procedure, social support following
surgery, preclusive co-morbidities). In addition, there may be dif-
ferences in health systems within and between countries that
might inﬂuence the generalizability of the study ﬁndings.
These confounding factors must be recorded on an individual
level or accounted for in the inclusion/exclusion criteria when time
to surgery is used as a primary outcome.
Time to return to activity. Some rehabilitation trials, particularly
post-operative rehabilitation trials, may consider time to return to
work, sport, or recreational activity as an important outcome
measure. These can also be assessed using time-to-event analysis.
Similar to using time to surgery as an outcome, the decision to
return to work, sport, or recreational activity may be inﬂuenced by
environmental, health-related, and psycho-social factors. Again,
these factors may need to be recorded on an individual level or
accounted for in the inclusion/exclusion criteria when time to ac-
tivity is used as a primary outcome.
Medication consumption. The use of rehabilitation interventions to
eliminate or reduce the need for pharmacological management of
symptoms is common. The type, dose, method of administration
and frequency of analgesic, NSAID or symptom-modifying medi-
cation use should be recorded.Physical activity and participation. The goals of many rehabilitation
interventions are to improve physical activity and, ultimately, in-
crease participation. If the outcome is to directly measure activity
intensity or duration, investigators should use accelerometer-based
measures of activity. In larger trials, the costs and time associated
with accelerometer-based measures of physical activity may be
prohibitive, in which case self-reported scales that have been
validated in the target OA population may be used. These in-
struments include the Lower-Extremity Activity Scale, University of
California Los Angeles Physical Activity Scale, The Physical Activity
Scale for the Elderly, and the Human Activity Proﬁle, among oth-
ers40e42. The choice of accelerometer and/or speciﬁc self-reported
physical activity measures should be based on the individual
study goals as the reliability and validity of these measures are
dependent on aims of the clinical trial41. Furthermore, we need to
acknowledge that the validity of some of these physical activity
questionnaires is limited.43
Psychological measures. There is a reciprocal interrelation between
depression and musculoskeletal pain44. Given the inﬂuence of
psychological status on the magnitude of pain and the efﬁcacy of
rehabilitation interventions in this population, psychological
measures that capture self-efﬁcacy, anxiety, depression, coping
strategies and pain catastrophizing may be important metrics to
include as outcome measures or as covariates for statistical ana-
lyses. Examples include the Arthritis Self-Efﬁcacy Scale45, Beck
Anxiety Index46, Centers for Epidemiological Studies Depression
Scale47, Coping Strategies Questionnaire48, and Pain Catastrophiz-
ing Scale49, respectively.
Biomarkers and imaging. Although the aims of most symptom-
modifying interventions are to reduce pain and improve function,
some interventions may concomitantly delay joint deterioration or
impact overall joint structure and metabolism (e.g., biomechanical,
bracing or orthoses, weight loss or activity interventions). Bio-
markers of structural OA progression or imaging of joint structure
may be appropriate for interventions that may have an associated
positive or negative structural or metabolic effect. Readers are
referred to the recommendations established by the Imaging and
Biochemical markers sub-groups, respectively.
Cost-effectiveness. We recommend that incremental cost-
effectiveness and/or incremental cost-utility ratios (ICURs) be
used as cost-effectiveness outcome measures for rehabilitation
trials that aim to evaluate cost-effectiveness of intervention ap-
proaches50. The incremental cost-effectiveness ratio (ICER) is an
estimate of differences in costs of healthcare in relation to differ-
ences in the health outcomes obtained between groups, and is
calculated by dividing the difference in healthcare costs between
groups by the difference in the health outcome measure between
groups51. The ICUR is an estimate of differences in costs of health-
care in relation to societal value of the resulting health outcomes
(utility)51. Utility is usually represented by quality-adjusted life
years (QALY). The ICUR is calculated by dividing the difference in
healthcare costs between groups by the difference in QALYs be-
tween groups over the study follow-up period.
When using ICERs or ICURs as outcome measures, the methods
for estimating costs, health outcomes, and health outcomes utility
should be described. The estimation of cost should reﬂect direct
and indirect costs for managing the participants' care. Direct
medical costs can include items such as physician or other
healthcare professional ofﬁce visits, medical/surgical tests and
procedures, medications, devices, equipment, etc. Non-medical
direct costs are costs to the individual that may result from
seeking medical attention or following through with medical
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home care, etc. Indirect costs may include items such as lost wages
to the patient or family members, parking fees, home renovations,
etc. Self-report instruments are commonly used and are acceptable
for obtaining information to estimate direct and indirect healthcare
costs.52
Response criteria
In addition to evaluating differences between groups in the
primary and secondary outcomes, responder rates of clinically
meaningful differences can be quantiﬁed for the study population.
The OARSI Standing Committee for Clinical Trials Response Criteria
Initiative has identiﬁed responder criteria based on absolute and
relative changes in pain, function and global assessment domains53.
It should be noted that these criteria are primarily derived from
pharmacological trials and implementation into rehabilitation tri-
als has not been fully evaluated. Variable-speciﬁc clinically mean-
ingful differences or changes should be considered when
evaluating response criteria. Investigators are cautioned however,
to take care in interpreting minimally important differences. As
stated by King;
“There is no universal MID, despite the appeal of the notion.
Indeed, for a particular patient-reported outcome instrument or
scale, the MID is not an immutable characteristic, but may vary
by population and context. At both the group and individual
level, the MID may depend on the clinical context and decision
at hand, the baseline fromwhich the patient starts, and whether
they are improving or deteriorating. Speciﬁc estimates of MIDs
should therefore not be overinterpreted.”
Benchmarking outcomes to established values
Outcomes from all arms of the clinical trial may be compared to
previously established age- or condition-matched normative values
if available. Benchmarking outcomes from a rehabilitation clinical
trial reduces the possibility of identifying a superior treatment that
fails to meet or exceed known outcomes.
Statistical considerations
Details for addressing the description of statistical analysis
procedures and reporting of results can be obtained in the article
concerning statistical considerations that accompanies this special
issue. Here we provide some basic information that should be
included in describing data analysis and reporting of results for
rehabilitation clinical trials.
Sample size estimates should be described for primary outcome
variables. The description should include the statistical test for
which the sample size was estimated (e.g., two way analysis of
variance, etc.) as well as the effect size, level of statistical signiﬁ-
cance, level of statistical power, and the expected dropout rate that
were used to calculate the sample size estimate. The sources used
to justify the effect size and expected drop out rates should be
provided in the description so that the reader has enough infor-
mation to reproduce the sample size estimates presented by the
authors.
Methods used for randomization and allocation concealment
should be described. The description should include the conditions
under which stratiﬁcation and/or block allocation methods were
employed if applicable. If computer generated methods or online
services for randomization were used this should be indicated. If
online services are publicly available they should be cited in the
manuscript. The method for allocation concealment (computer
generated electronic notiﬁcation, sealed envelope, etc.) should be
described.A description of all statistical tests used in the study should be
provided. Primary focus should be given to the primary outcomes
of the study and all additional analyses should be described as
secondary analyses. It may be helpful to present the description of
statistical tests as it relates to each aim in the study (e.g., “to
compare mean differences between groups over time on pain
scores, a two way repeated measures analysis of variance was
performed.”) There should be a description provided of how data
was screened to determine they met the assumptions for the tests
being used in the analysis (e.g., if parametric tests were used were
the data screened for normality, homogeneity of variance, etc.) The
level of signiﬁcance for each statistical test should be stated and
there should be a description of methods used to adjust formultiple
comparisons if applicable. If interim analyses were performed the
method to adjust for this should be described. Descriptions of any
adjustments for confounders/covariates should also be provided.
A statement should be provided indicating whether the analysis
was performed using intention-to-treat methods or as-treated
analyses (as may be the case in efﬁcacy trials) were employed. If
intention-to-treat methods are used, then the methods for dealing
with missing data (e.g., multiple imputation, last score forward,
etc.) should also be described. It may be helpful to characterize the
missing data as missing completely at random, missing at random,
or not missing at random.
There are many methods for reporting the results of clinical
trials that often include the use of data tables, charts and ﬁgures.
Regardless of the method an author may select, there are certain
elements that we recommend be included in reporting of results for
rehabilitation trials. These elements would facilitate the use of the
study data in subsequent systematic reviews and meta-analyses.
The means, standard deviations, and 95% conﬁdence intervals
(CIs) should be provided for the primary outcome for each study
group. Authors should also report mean differences and the stan-
dard deviations and 95% CIs of the differences between groups for
the primary outcome. In cases where loss to follow-up may have
occurred, the sample size for each group inwhich the analyses were
performed should also be provided.Author contributions
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